Question 1

What is AskBio?

Accepted Answer

AskBio is a Entity.

Question 2

How often does AskBio appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 6 articles.

Question 3

When was AskBio first tracked by Ergen?

Accepted Answer

First tracked on Apr 01, 2026.

Question 4

When was AskBio last mentioned in news?

Accepted Answer

Last active on May 14, 2026.

Question 5

What is AskBio's current news sentiment?

Accepted Answer

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is AskBio in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving AskBio?

Accepted Answer

AskBio completes AB-1002 trial enrollment (Apr 01, 2026, 6 articles).

Question 8

How did the "AskBio completes AB-1002 trial enrollment" event impact AskBio?

Accepted Answer

AskBio announced the completion of enrollment for its GenePHIT Phase 2 clinical trial of AB-1002, a significant milestone in its heart failure clinical program. This advancement could lead to a new treatment for heart failure, positively impacting AskBio's future prospects.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.